drugset / Trial / NCT02451488

Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma

NCT02451488

Phase 4 Completed 8 enrolled Mayo Clinic
RandomizedParallel-groupOpen-labelTreatment

Summary

Randomized trial to determine if neo-adjuvant subcutaneous GM-CSF restores the host regional lymph node immunity

Timeline

Start
2015-05
Primary completion
2016-11-04
Completion
2016-11-04

Drugs

EvaluationDrugModalityDoseRoute
Subject sargramostim Protein / enzyme biologic 125 ug/m2 Subcutaneous

Indications